DLC1 Is a Prognosis-Related Biomarker Correlated With Tumor ...
www.frontiersin.org › articles › full
Background and AimDeleted in liver cancer 1 (DLC1) is confirmed as a metastasis suppressor gene in endometrial carcinoma (EC).
People also ask
Is Frontiers in Oncology peer reviewed?
All articles submitted to Frontiers are subjected to review without selection bias. Our peer review system is designed to be unbiased, efficient and transparent.
What are the causes of cancer?
Cancer is caused by certain changes to genes, the basic physical units of inheritance. Genes are arranged in long strands of tightly packed DNA called chromosomes. Cancer is a genetic disease—that is, it is caused by changes to genes that control the way our cells function, especially how they grow and divide.
Oncol.</journal-id> <journal-title>Frontiers in ... full#supplementary-material">https://www.frontiersin.org ... Oncology</article-title>. <source>Nat Rev Clin ...
Highlights research in carcinogenesis and tumor progression, bridging the gap between basic research and clinical applications to advance diagnosis, ...
Missing: 2022.823018/ | Show results with:2022.823018/
Deleted in liver cancer 1 (DLC1) is confirmed as a metastasis suppressor gene in endometrial carcinoma (EC). However, its functional mechanisms remain unclear.
Highlights research in carcinogenesis and tumor progression, bridging the gap between basic research and clinical applications to advance diagnosis, ...
Missing: 2022.823018/ full
People also search for
Related conditions
For informational purposes only. Consult your local medical authority for advice.
Feb 11, 2022 · Background and Aim Deleted in liver cancer 1 (DLC1) is confirmed as a metastasis suppressor gene in endometrial carcinoma (EC).
Jul 29, 2022 · Chemotherapy has historically been the mainstay of cancer treatment, but our understanding of what drives a successful therapeutic response ...
Missing: 2022.823018/ | Show results with:2022.823018/
IntroductionPembrolizumab combined with chemotherapy has become the standard of care for patients with non-small-cell lung cancer (NSCLC) ...
Missing: 2022.823018/ | Show results with:2022.823018/
Dec 21, 2023 · Discussion: We conclude that the PODO447 glycoepitope is an excellent biomarker of immune “cold” tumors and a candidate for the development of ...
Missing: 2022.823018/ | Show results with:2022.823018/
Full text. Journal: Cancers, 2019, № 11, p. 1734 ... Publications that cite this publication ... https://doi.org/10.3389/fonc.2022.823018 ·. 2022, Frontiers in ...
Missing: articles/ | Show results with:articles/